Antisense Oligonucleotides Modulating Tau Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and progressive supranuclear palsy lack effective options for reducing Tau protein levels, which are associated with neuronal toxicity and cognitive impairment.
Innovation Solution
The use of antisense compounds, specifically antisense oligonucleotides, to modulate the expression of Tau mRNA and protein by targeting Tau nucleic acids, thereby reducing Tau levels in animals, including humans, to prevent or treat neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then existing therapeutic options are maintained, but effective reduction of Tau protein levels is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of oligonucleotide molecules to create antisense compounds with enhanced properties. Specifically, the invention introduces modified sugar moieties (such as 2'-O-methoxyethyl and bicyclic sugars) and modified internucleoside linkages (such as phosphorothioates) to alter the physical and chemical parameters of the oligonucleotide, thereby improving its stability, binding affinity, and ability to reduce Tau protein levels effectively
Solution Approach 2:
The patent employs composite materials by creating chimeric oligonucleotide structures that combine different types of nucleosides and linkages within a single molecule. The antisense compounds consist of composite sequences containing both modified and unmodified nucleotides, allowing the molecule to exhibit multiple functions: high-specificity binding to Tau mRNA, resistance to nucleases, and effective induction of mRNA degradation, thus achieving reliable Tau protein reduction
2Reliability
If Tau protein levels are reduced to treat neurodegenerative diseases, then disease progression may be slowed, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting only the specific Tau mRNA sequences that encode the pathological Tau protein. The antisense compounds are designed to bind specifically to complementary sequences in the Tau mRNA, extracting or removing the harmful genetic information without affecting other cellular processes. This specificity simplifies the treatment approach by focusing solely on the disease-causing element
Solution Approach 2:
The patent uses antisense oligonucleotide compounds as intermediary molecules that mediate between the cellular machinery and the Tau mRNA target. These intermediary compounds facilitate the specific recognition and degradation of Tau mRNA by cellular enzymes (such as RNase H), thereby reducing Tau protein production without requiring direct manipulation of the Tau gene or complex delivery systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively decreases Tau protein levels, potentially ameliorating or slowing the progression of Tau-associated diseases by targeting the underlying cause of neurodegeneration.
Implementation Method 1
antisense compounds, specifically antisense oligonucleotides, to modulate the expression of Tau mRNA and protein by targeting Tau nucleic acids
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.